Compare DexCom, Inc. (DXCM) vs MobilEye Global Inc (MBLY) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Mobileye (MBLY) trades at $8.91, down 11.69% on the day, reflecting market volatility amid mixed signals. The stock shows a neutral technical stance with key support at $8 and resistance at $10. Fundamentally, the company reported a net loss of $392 million for 2025 despite $1.89 billion in revenue, with a negative net income margin of -203.97% for 2026. Recent news highlights its strategic pivot to launch a vertically integrated U.S. robotaxi service in 2027, generating significant media attention.

The outlook hinges on Mobileye's execution of its robotaxi initiative, which offers substantial growth potential but carries high execution risk. Analyst consensus is bullish with a $10.71 price target, though profitability challenges and intense competition in autonomous driving pose significant headwinds. Investors should weigh the long-term transformative opportunity against near-term financial losses and market skepticism.